Ultragenyx Pharmaceutical (RARE) Revenue & Revenue Breakdown
Ultragenyx Pharmaceutical Revenue Highlights
Latest Revenue (Y)
$434.25M
Latest Revenue (Q)
$147.03M
Main Segment (Y)
Royalty
Main Geography (Y)
North America
Ultragenyx Pharmaceutical Revenue by Period
Ultragenyx Pharmaceutical Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $434.25M | 19.52% |
| 2022-12-31 | $363.33M | 3.39% |
| 2021-12-31 | $351.41M | 29.66% |
| 2020-12-31 | $271.03M | 161.32% |
| 2019-12-31 | $103.71M | 101.41% |
| 2018-12-31 | $51.49M | 1871.48% |
| 2017-12-31 | $2.61M | 1863.91% |
| 2016-12-31 | $133.00K | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2012-12-31 | - | 100.00% |
| 2011-12-31 | - | - |
Ultragenyx Pharmaceutical generated $434.25M in revenue during NA 2023, up 19.52% compared to the previous quarter, and up 843.28% compared to the same period a year ago.
Ultragenyx Pharmaceutical Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $147.03M | 35.09% |
| 2024-03-31 | $108.83M | -14.57% |
| 2023-12-31 | $127.39M | 29.92% |
| 2023-09-30 | $98.05M | -9.47% |
| 2023-06-30 | $108.31M | 7.77% |
| 2023-03-31 | $100.50M | -2.76% |
| 2022-12-31 | $103.35M | 13.94% |
| 2022-09-30 | $90.70M | 1.52% |
| 2022-06-30 | $89.34M | 11.77% |
| 2022-03-31 | $79.94M | -4.14% |
| 2021-12-31 | $83.39M | 2.13% |
| 2021-09-30 | $81.65M | -6.13% |
| 2021-06-30 | $86.97M | -12.50% |
| 2021-03-31 | $99.39M | 8.58% |
| 2020-12-31 | $91.54M | 12.36% |
| 2020-09-30 | $81.47M | 32.02% |
| 2020-06-30 | $61.71M | 69.96% |
| 2020-03-31 | $36.31M | 2.01% |
| 2019-12-31 | $35.59M | 37.96% |
| 2019-09-30 | $25.80M | 6.84% |
| 2019-06-30 | $24.15M | 32.89% |
| 2019-03-31 | $18.17M | 11.75% |
| 2018-12-31 | $16.26M | 38.24% |
| 2018-09-30 | $11.76M | -8.06% |
| 2018-06-30 | $12.79M | 19.83% |
| 2018-03-31 | $10.68M | 342.29% |
| 2017-12-31 | $2.41M | 1119.19% |
| 2017-09-30 | $198.00K | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | -100.00% |
| 2016-12-31 | $5.00K | -95.50% |
| 2016-09-30 | $111.00K | 552.94% |
| 2016-06-30 | $17.00K | 100.00% |
| 2016-03-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2013-09-30 | - | 100.00% |
| 2013-06-30 | - | 100.00% |
| 2013-03-31 | - | 100.00% |
| 2012-12-31 | - | - |
Ultragenyx Pharmaceutical generated $147.03M in revenue during Q2 2024, up 35.09% compared to the previous quarter, and up 146.30% compared to the same period a year ago.
Ultragenyx Pharmaceutical Revenue Breakdown
Ultragenyx Pharmaceutical Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Collaboration And License | $71.18M | $7.69M | $85.00M | $89.22M | $504.00K |
| Royalty | $182.65M | - | - | - | - |
| Product | $180.41M | - | - | - | - |
Ultragenyx Pharmaceutical's latest annual revenue breakdown by segment (product or service), as of Dec 23: Royalty (42.06%), Product (41.55%), and Collaboration And License (16.39%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $73.81M | $62.49M | $138.06M | $42.35M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Royalty | $73.22M | $46.34M | $126.95M | $55.70M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Collaboration And License | - | - | $69.70M | $1.48M | $1.48M | $1.48M | $1.48M | $3.25M | $8.23M | $12.06M | $21.96M | $42.75M | $37.50M | $32.87M | $18.86M | $51.00K | $101.00K | $68.00K | $284.00K | - |
Ultragenyx Pharmaceutical's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Product (50.20%), and Royalty (49.80%).
Ultragenyx Pharmaceutical Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| North America | $307.15M | $281.09M | $301.11M | $237.67M | - |
| Europe | $47.53M | $36.37M | $26.66M | $21.32M | $12.09M |
| JAPAN | $2.22M | $1.16M | - | - | - |
| Latin America | $77.34M | $44.71M | - | - | - |
| All Other | - | - | $23.64M | $12.05M | $5.19M |
| UNITED STATES | - | - | - | - | $86.44M |
Ultragenyx Pharmaceutical's latest annual revenue breakdown by geography, as of Dec 23: North America (70.73%), Latin America (17.81%), Europe (10.95%), and JAPAN (0.51%).
Quarterly Revenue by Country
| Country | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Latin America | $38.93M | $35.18M | $18.25M | $17.23M | $19.07M | $22.80M | $8.26M | $14.12M | $12.54M | $9.79M | $7.49M | $4.71M | - | - | - | - | - | - | - | - |
| North America | $88.89M | $57.68M | $92.92M | $67.81M | $79.29M | $67.13M | $70.89M | $66.91M | $75.57M | $87.74M | $82.73M | $72.65M | - | - | - | - | - | - | - | - |
| EMEA | $16.16M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Asia Pacific | $3.05M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| JAPAN | - | - | $1.05M | - | - | $1.18M | - | $1.16M | - | - | - | - | - | - | - | - | - | - | - | - |
| Europe | - | $15.97M | $15.18M | $13.01M | $9.95M | $9.39M | $10.26M | $8.41M | $9.48M | $8.23M | $7.08M | $7.24M | $6.70M | $5.64M | $5.61M | $5.00M | $6.55M | $4.16M | $3.56M | $2.79M |
| U.S. and Canada | - | - | - | - | - | - | - | $67.01M | $67.33M | $61.92M | - | - | - | - | - | - | - | - | - | - |
| All Other | - | - | - | - | - | - | - | - | - | - | - | - | - | $6.02M | $3.20M | $3.82M | $3.23M | $1.79M | $1.91M | $1.31M |
| UNITED STATES | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $51.93M | $30.36M | $30.12M | $21.70M |
Ultragenyx Pharmaceutical's latest quarterly revenue breakdown by geography, as of Jun 24: North America (60.46%), Latin America (26.48%), EMEA (10.99%), and Asia Pacific (2.08%).
Ultragenyx Pharmaceutical Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| INCY | Incyte | $3.70B | $1.04B |
| UTHR | United Therapeutics | $2.33B | $714.90M |
| ALNY | Alnylam Pharmaceuticals | $1.83B | $659.83M |
| RARE | Ultragenyx Pharmaceutical | $434.25M | $147.03M |
| AMLX | Amylyx Pharmaceuticals | $380.79M | $88.64M |
| APLS | Apellis Pharmaceuticals | $366.28M | $179.14M |
| ARVN | Arvinas | $78.50M | $76.50M |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| CRNX | Crinetics Pharmaceuticals | $4.01M | $640.00K |
| XFOR | X4 Pharmaceuticals | - | $563.00K |
| PDSB | PDS Bio | - | - |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| ABOS | Acumen Pharmaceuticals | - | - |
| INZY | Inozyme Pharma | - | - |
| KURA | Kura Oncology | - | - |
| TERN | Terns Pharmaceuticals | - | - |
RARE Revenue FAQ
What is Ultragenyx Pharmaceutical’s yearly revenue?
Ultragenyx Pharmaceutical's yearly revenue for 2023 was $434.25M, representing an increase of 19.52% compared to 2022. The company's yearly revenue for 2022 was $363.33M, representing an increase of 3.39% compared to 2021. RARE's yearly revenue for 2021 was $351.41M, representing an increase of 29.66% compared to 2020.
What is Ultragenyx Pharmaceutical’s quarterly revenue?
Ultragenyx Pharmaceutical's quarterly revenue for Q2 2024 was $147.03M, a 35.09% increase from the previous quarter (Q1 2024), and a 35.75% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $108.83M, a -14.57% decrease from the previous quarter (Q4 2023), and a 8.30% increase year-over-year (Q1 2023). RARE's quarterly revenue for Q4 2023 was $127.39M, a 29.92% increase from the previous quarter (Q3 2023), and a 23.27% increase year-over-year (Q4 2022).
What is Ultragenyx Pharmaceutical’s revenue growth rate?
Ultragenyx Pharmaceutical's revenue growth rate for the last 3 years (2021-2023) was 23.57%, and for the last 5 years (2019-2023) was 318.70%.
What are Ultragenyx Pharmaceutical’s revenue streams?
Ultragenyx Pharmaceutical's revenue streams in c 23 are Collaboration And License, Royalty, and Product. Collaboration And License generated $71.18M in revenue, accounting 16.39% of the company's total revenue, up 826.15% year-over-year. Royalty generated $182.65M in revenue, accounting 42.06% of the company's total revenue Product generated $180.41M in revenue, accounting 41.55% of the company's total revenue
What is Ultragenyx Pharmaceutical’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Ultragenyx Pharmaceutical was Royalty. This segment made a revenue of $182.65M, representing 42.06% of the company's total revenue.